Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …

Drug-induced gene expression profiling provides a lot of useful information covering various
aspects of drug discovery and development. Most importantly, this knowledge can be used …

Simple Summary Triple-negative breast cancer (TNBC) is one of the most aggressive breast
cancer subtypes, largely due to heterogeneity and lack of treatment options. Due to absence …

Triple-negative breast cancer (TNBC) has the worst prognosis among the subtypes of breast
cancer, with no targeted therapy available. Immunotherapy targeting programmed cell death …

Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers
characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 …

Simple Summary Triple negative breast cancer lacks targeted therapies and has poor
prognosis; chemotherapy is currently the main treatment modality. Growing evidence has …

Stage I–III triple-negative breast cancer accounts for approximately 15–20% of new
diagnoses of early breast cancer. Novel systemic treatment options have recently been …

Annexin A1 (AnxA1) is a pleiotropic protein that exerts essential roles in breast cancer (BC)
growth and aggressiveness. In our previous work, we described the autocrine signaling of …

Triple-negative breast cancer (TNBC) constitutes a heterogeneous group of malignancies
that are often aggressive and associated with a poor prognosis. The development of new …